-$0.86 Earnings Per Share Expected for Trillium Therapeutics Inc. (TRIL) This Quarter
Analysts expect Trillium Therapeutics Inc. (NASDAQ:TRIL) (TSE:TR) to report earnings per share of ($0.86) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Trillium Therapeutics’ earnings, with estimates ranging from ($1.07) to ($0.75). Trillium Therapeutics reported earnings per share of ($0.78) during the same quarter last year, which would suggest a negative year over year growth rate of 10.3%. The company is expected to report its next earnings results on Thursday, November 9th.
On average, analysts expect that Trillium Therapeutics will report full-year earnings of ($3.91) per share for the current financial year, with EPS estimates ranging from ($4.78) to ($2.89). For the next year, analysts expect that the company will post earnings of ($3.17) per share, with EPS estimates ranging from ($3.88) to ($2.72). Zacks’ earnings per share averages are an average based on a survey of sell-side analysts that that provide coverage for Trillium Therapeutics.
Several analysts have recently weighed in on TRIL shares. Zacks Investment Research downgraded Trillium Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, September 1st. HC Wainwright started coverage on Trillium Therapeutics in a research report on Monday, July 17th. They set a “buy” rating and a $7.00 target price for the company. Ladenburg Thalmann Financial Services reiterated a “buy” rating and set a $18.00 target price on shares of Trillium Therapeutics in a research report on Friday, June 9th. Finally, Cowen and Company reiterated a “buy” rating on shares of Trillium Therapeutics in a research report on Wednesday, July 5th. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $14.95.
Trillium Therapeutics (TRIL) opened at 5.00 on Thursday. Trillium Therapeutics has a 12 month low of $4.15 and a 12 month high of $17.70. The firm’s 50-day moving average is $4.65 and its 200-day moving average is $5.27. The stock’s market capitalization is $53.97 million.
Several large investors have recently added to or reduced their stakes in TRIL. NEA Management Company LLC bought a new stake in shares of Trillium Therapeutics during the second quarter worth $4,619,000. AWM Investment Company Inc. bought a new stake in shares of Trillium Therapeutics during the second quarter worth $4,415,000. Janus Henderson Group PLC bought a new stake in shares of Trillium Therapeutics during the second quarter worth $2,395,000. Tekla Capital Management LLC bought a new stake in shares of Trillium Therapeutics during the second quarter worth $1,980,000. Finally, Victory Capital Management Inc. lifted its position in shares of Trillium Therapeutics by 88.9% during the second quarter. Victory Capital Management Inc. now owns 146,571 shares of the biotechnology company’s stock worth $645,000 after purchasing an additional 68,970 shares during the last quarter. Institutional investors and hedge funds own 47.97% of the company’s stock.
About Trillium Therapeutics
Trillium Therapeutics Inc, a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The companys lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced hematologic malignancies and solid tumors therapy.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Stock Ratings for Trillium Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trillium Therapeutics Inc. and related stocks with our FREE daily email newsletter.